A medical food product to address common underlying genetic metabolic imbalances and improve retinal blood flow. Retinal ischemia is preceded by endothelial dysfunction and often with elevated homocysteine (Hcy). By addressing these underlying metabolic abnormalities which lowers Hcy, Ocufolin™ has been shown to increase both retinal and conjunctival tissue perfusion.
In 2020, two new clinical studies using Ocufolin™ were conducted and published by the Bascom Palmer Eye Institute (U of Miami). The trial results matched and extended original clinical observations leading to the formulation of Ocufolin™.
Our mission is to serve the eye care industry with peer reviewed clinical data and innovative insights for improving the care of retinal ischemia and retinal endothelial injury. This focus has guided our work for more than a decade and culminates in the launch of Ocufolin™. This product is the embodiment of our best practices, our best science and manufacturing processes. We trust that it will serve the needs of your patients as it has for ours. We look forward to speaking with you.
Ocufolin® is classified as a medical food that can only be sold under medical supervision. Ask your eye care provider or pharmacist if Ocufolin® may be right for you. That medical professional has the authority to order the product for you.
Please contact us for distribution details.